Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCI699 (Osilodrostat) in Essential Hypertension
NCT00758524Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2008
- Primary completion
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of osilodrostat in essential hypertension, sponsored by Novartis. Started Sep 2008; status: completed.
02
Drugs
osilodrostat
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00758524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00758524.